Roghayeh Tarasi

Roghayeh Tarasi

Auto-generated profile, based on publicly available information

Roghayeh Tarasi

Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Scientific Journal of Kurdistan University of Medical Sciences
Verified
Journal Article
Open access
PDF file
MPMohammad Pourali
Mohammad Pourali
RTRoghayeh Tarasi
Roghayeh Tarasi
TTTahereh Tayebi
Tahereh Tayebi
HNHassan Niknejad
Hassan Niknejad
Background and Aim: Tissue adhesives are increasingly used instead of sutures or staples to close wounds in modern medicine. It seems that use of tissue adhesives can lead to faster and easier closure of the surgical wounds in comparison to sutures. Moreover, tissue glues have a wide application in the fields ...

3 August 2026 in EXCLI Journal
Verified
Journal Article
Open access
PDF file
JKJavad Khanali
Javad Khanali
YOYasamin Ostadi
Yasamin Ostadi
FTFatemeh A. Tehrani
Fatemeh A. Tehrani
TTTahereh Tayebi
Tahereh Tayebi
RTRoghayeh Tarasi
Roghayeh Tarasi
HNHassan Niknejad
Hassan Niknejad
Decellularized extracellular matrices (DEMs) have been widely investigated as promising biomaterials for soft tissue augmentation. In contrast, the use of decellularized human amniotic membrane (dHAM) represents a novel approach within this field, offering unique potential for clinical application. The objective of this study is to develop an “off-the-shelf” bioactive soft tissue filler from crosslinked and non-crosslinked dHAM in the injectable microparticle formulation. We used physical and enzymatic processes for decellularization and milling for fabricating the injectable matrix. The decellularization, crosslinking and detoxification protocol removed immunogenic cellular components, preserved collagen and glycosaminoglycan content, and reduced residual crosslinker to sub-cytotoxic levels. Consequently, both crosslinked and non-crosslinked powder extractions promoted cell viability and proliferation and did not affect cell migration in culture. Moreover, the crosslinked powder showed higher stability upon in vitro enzymatic degradation and prolonged volume retention in the subcutaneous guinea pig model. Histopathologic evaluation of the implants showed that immune cell infiltration markedly resolved over the 12-week study period. Moreover, immunohistochemistry staining for CD68 and CD163 macrophage markers indicated the abundance of CD163-positive cells, commonly associated with an anti-inflammatory or M2-like phenotype. Staining for CD31 endothelial cell marker demonstrated the formation of blood vessels with intraluminal RBCs and endothelial cell lining within the implants, which is indicative of neovascularization. Therefore, dHAM demonstrated long-term volume retention, reduced immune cell infiltration, and was associated with a CD163-positive macrophage phenotype and evidence of vascularization in the animal model. This study suggests dHAM as a readily deliverable biomaterial and a promising candidate to address clinical translational needs for soft tissue reconstruction.